Abstract
The binding characteristics of RU 486 with the glucocorticoid receptor (GR) and the progestin receptor (PR) were studied in order to explain the potent antiglucocorticoid and antiprogestin activities of the compound. In vitro, (3H)RU 486 bound to the same cytosol receptors as (3H) dexamethasone (GR) and (3H)R 5020 (PR); the sedimentation coefficients, number of binding sites and specificity were similar. However, the affinity of (3H)RU 486 for these receptors was higher than that of the potent agonists, as indicated by the high affinity constant determined from Scatchard plots and by the slow dissociation rates from the GR and PR. With the cytosol receptor under heat activation, the agonists were able to give rise to more stable complexes, but (3H)RU 486 dissociated faster from the activated than from the non-activated GR. This impeded activation of the (3H)RU 486-GR complex was confirmed by observations of its lower affinity than that of (3H)dexamethasone-GR complex for DNA-cellulose and by a low retention in the nucleus that may be related to RU 486’s lack of glucocorticoid activity. Conversely, the uterine (3H)RU 486-PR complex did not undergo an acceleration of dissociation rate under heat activation, and its affinity for DNA-cellulose was similar to that of the activated (3H)R 5020-PR complex. This led to a high level of nuclear retention unrelated to the lack of progestin activity of RU 486. In contrast to in vitro interaction, high in vivo doses of RU 486 were needed to interact with the cytosol receptors in the rat; this cannot be explained by a binding to rat plasma protein.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baulieu, E. E., and Raynaud, J. P., 1970, a “proportion graph” method for measuring binding systems, Europ. J. Biochem., 13: 293.
Bourgeois, S., Pfahl, M., and Baulieu, E. E.., 1984, DNA binding properties of glucocorticosteroid receptors bound to the steroid antagonist RU 486, EMBO Journal, 3: 751.
Chasserot-Golaz, S., and Beck, G., 1984, an approach to the mechanism of the potent antiglucocorticoid: 17ß-hydroxy-118–4-dimethyl-aminophenyl-l7ßpropynyl-estra-4, 9-dien-3-one, submitted to J. Steroid Biochem.
Deraedt, R., Bonnat, C., Busigny, M., Chatelet, P., Cousty, C., Mouren, M., Philibert, D., Pottier, J., and Salmon, J., Pharmacokinetics of RU 486, this volume.
Gravanis, A., Schaison, G., George, M., Satyaswaroop, P. G., Saulieu, E. E., and Robel, P., 1985, Endometrial and pituitary responses to the anti-progesterone steroid RU 486 in post-menopausal women, J. Clinical Endocrinol. Metab., 60: 156.
Jung-Testas, I., and Saulieu, E. E., 1984, Anti-steroid action in cultured L-929 mouse fibroblasts, J. Steroid Biochem., 20: 301.
Kalimi, M., Colman, P., and Feigelson, P., 1975, the “activated” hepatic glucocorticoíd receptor complex. Its generation and properties, J. Biol. Chem., 10: 1080.
King, W. J., and Greene, G. L., 1984, Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells, Nature, 307: 745.
McEwen, B. S., and Zigmond, R. E., 1972, Isolation of brain cell-nuclei, in: “Method in Neurochemistry,” N. Marks and R. Rodnight, eds., Plenum Press, New York, pp 140–61.
Moguilewsky, M., and Philibert, D., 1984, RU 38486: potent antiglucocorticoid activity correlated with strong binding to the cytosolic glucocorticoid receptor followed by an impaired activation, J. Steroid Biochem., 20: 271.
Ojasso, T., and Raynaud, J. P., 1978, Unique congeners for receptor studies, Cancer Res., 38: 4186.
Philibert, D., 1984, RU 38486: an original multifaceted antihormone in vivo, in: “Adrenal Steroid Antagonism,” K. W. Agarwal, ed., Walter de Gruyter Co., Berlin and New York, pp 77–101.
Philibert, D., Moguilewsky, M., Mary, I., Lecaque, D., Tournemine, C., Secchi, J., and Deraedt, R., Pharmacological profile of RU 486, this volume.
Raynaud, J. P., Bonne, C., Bouton, M. M., Moguilewsky, M., Philibert, D., and Azadian-Boulanger, G., 1975, Screening for anti-hormones by receptor studies, J. Steroid Biochem., 6: 615.
Raynaud, J. P., Bouton, M. M., and Ojasoo, T., 1980, The use of interaction kinetics to distinguish potential antagonists from agonists, TIPS: 324.
Rochefort, H., and Borgna, J. L., 1981, Differences between oestrogen receptor activation by oestrogen and antioestrogen, Nature, 292: 257.
Schrader, W. T., 1984, New Model for steroid hormone receptors, Nature, 308: 17.
Schmidt, T. J., and Litwack, G., 1982, Activation of the glucocorticoid receptor complex, Physiol. Rev., 62: 1131.
Seeley, D. H., and Costas, P. D., 1983, Transformation of a rabbit progesterone receptor from an 8S form to 5.5S and 4S forms, Mol. Cell. Endocr., 30: 161.
Shyamala, G., and Leonard, L., 1980, Inhibition of uterine estrogen receptor transformation by sodium molybdate, J. Biol. Chem., 255: 6028.
Weichman, B. M., and Notides, A. C., 1977, Estradiol-binding kinetics of the activated and nonactivated estrogen receptor, J. Biol. Chem., 252: 8856.
Wolfson, A., Mester, J., Chang-Ren, Y., and Baulieu, E. E., 1980, “Non-activated” form of the progesterone receptor from chick oviduct: characterization, Biochem. Biophys. Res. Commun., 95: 1577.
Welshons, W. V., Lieuerman, M. E., and Gorski, J., 1984, Nuclear localization of unoccupied oestrogen receptors, Nature, 307: 747.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Plenum Press, New York
About this chapter
Cite this chapter
Moguilewsky, M., Philibert, D. (1985). Biochemical Profile of RU 486. In: Baulieu, EE., Segal, S.J. (eds) The Antiprogestin Steroid RU 486 and Human Fertility Control. Reproductive Biology. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-1242-0_7
Download citation
DOI: https://doi.org/10.1007/978-1-4684-1242-0_7
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4684-1244-4
Online ISBN: 978-1-4684-1242-0
eBook Packages: Springer Book Archive